The findings of the new Phase 3 trial, which involved more than 32,000 participants, could boost confidence in the vaccine, which was originally developed by Oxford University. The trial showed the vaccine was well tolerated and there were no safety concerns, the company said. According to AstraZeneca, an independent committee …
Read More »